

Amendments to the Claims:

This listing of claims will replace all prior versions,
and listings, of claims in the application:

Listing of Claims

Claims 1-18 (canceled)

19. (new) A method for treating hepatitis
comprising administering to a patient in need thereof an
effective amount of a compound that neutralizes the
effect of secreted TNF alpha.

20. (new) The method according to claim 19
wherein the hepatitis is selected from the group
consisting of hepatitis A, hepatitis B, hepatitis C,
hepatitis D, and hepatitis E.

21. (new) The method according to claim 19
wherein the compound that neutralizes the effect of TNF
alpha is etanercept.

22. (new) The method according to claim 19
wherein the compound that neutralizes the effect of TNF
alpha is a humanized monoclonal antibody.

23. (new) The method according to claim 22
wherein the humanized monoclonal antibody is infliximab.

24. (new) The method according to claim 19
wherein the hepatitis is a viral hepatitis.

25. (new) The method according to claim 24

wherein the compound that neutralizes the effect of secreted TNF alpha is etanercept.

26. (new) The method according to claim 24 wherein the compound that neutralizes the effect of TNF alpha is a humanized monoclonal antibody.

27. (new) The method according to claim 26 wherein the humanized monoclonal antibody is infliximab.

28. (new) A method for treating viral hepatitis comprising administering to a patient in need thereof an effective amount of a compound that reduces viral levels in that patient.

29. (new) The method according to claim 28 wherein the compound that reduces the viral levels is a compound that neutralizes the effect of secreted TNF alpha.

30. (new) The method according to claim 28 wherein the hepatitis is selected from the group consisting of hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E.

31. (new) The method according to claim 29 wherein the compound that reduces the viral levels is etanercept.

32. (new) The method according to claim 28 wherein the compound that reduces the viral levels in a patient is a humanized monoclonal antibody.

Appl. No. 09/925,970
Amdt. Dated July 18, 2003
Reply to Office action of March 19, 2003

33. (new) The method according to claim 32
wherein the humanized monoclonal antibody is infliximab.
